ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Simultaneous Reversal of T Lymphocytes and Cancer Cells Metabolism Via a Biomimetic Heavy-Atom-Free Photosensitizers-Based Combination Therapies to Boost Cancer Photoimmunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Organic Nanozyme-Embedded Biotherapeutic Thermosensitive Hydrogel for Extracellular GSH Depletion and Postoperative Tumor Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering an immuno-nanoprodrug: Photo-controlled pyroptosis synergizing with acid-activatable immunometabolic blockade for potent cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- NIR-II Fluorescent Nanoplatforms with Defect-Regulated Piezoelectricity for Dual NIR-II/MRI-Guided, Hypoxia-Resilient Piezo-Chemodynamic Therapy and cGAS-STING Activation in Orthotopic Liver Tumor.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Biomimetic Organic Nanozyme as Tumor Vaccines for Targeted Suppression of Ammonia-Induced T Lymphocyte Death to Augment Breast Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Singlet oxygen-precharged injectable hydrogel triggers ferroptosis and lactate metabolism reprogramming for enhanced colorectal cancer immunotherapy.Journal of nanobiotechnology · 2026Article
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- Strategies, Challenges and Application Prospects for Exosome Engineering Modifications in Tumor Targeted Therapeutics.International journal of nanomedicine · 2026Review
- Immune Microenvironment of Hair Follicles in Tumor Immunotherapy.ImmunoTargets and therapy · 2026Review
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- Simultaneous Reversal of T Lymphocytes and Cancer Cells Metabolism Via a Biomimetic Heavy-Atom-Free Photosensitizers-Based Combination Therapies to Boost Cancer Photoimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Near-infrared (NIR) activated photosensitizers based on heavy-atom-free have great advantages in photoimmunotherapy, yet the tumor microenvironment often restricts their efficacy. To address this, a NIR-activated heavy-atom-free photosensitizer (named Cy-BF) is developed. Cy-BF is then encapsulated with phospholipids and platelet exosome vesicles to create platelet exosomes vesicles biomimetic and Cy-BF loaded hybrid liposomes (named CHL) Characterized by high phototoxicity, low dark toxicity, and enhanced tumor targeting, CHL demonstrates aggregation-induced broadening of absorption spectra and NIR (760 nm laser) activates photothermal therapy and type I photodynamic therapy. The CHL-mediated phototherapy induces mitochondrial damage and immunogenic cell death in tumor cells, decreases lactate production, and alters the tumor microenvironment by reducing regulatory T cells and increasing CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.